Voltar
Revisão Acesso aberto
BIBTEX RIS

Role of Mitogen-Activated Protein (MAP) Kinases in Cardiovascular Diseases

2006; Wiley; Volume: 23; Issue: 3 Linguagem: Inglês

10.1111/j.1527-3466.2005.tb00169.x

ISSN

1527-3466

Autores

Nilesh Pandya, D.D. Santani, Sunita Jain,

Tópico(s)

Synthesis and biological activity

Resumo

Cardiovascular Drug ReviewsVolume 23, Issue 3 p. 247-254 Free Access Role of Mitogen-Activated Protein (MAP) Kinases in Cardiovascular Diseases Nilesh Pandya, Corresponding Author Nilesh Pandya Department of Pharmacology, C. U. Shah College of Pharmacy & Research, Wadhwan City, Surendranagar, IndiaAddress correspondence and reprint requests to: Mr. N. Pandya, Department of Pharmacology, C. U. Shah College of Pharmacy & Research, Wadhwan City-363030, Dist. Surendranagar, India; E-mail: [email protected], [email protected]Search for more papers by this authorDev Santani, Dev Santani Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, IndiaSearch for more papers by this authorSunita Jain, Sunita Jain Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, IndiaSearch for more papers by this author Nilesh Pandya, Corresponding Author Nilesh Pandya Department of Pharmacology, C. U. Shah College of Pharmacy & Research, Wadhwan City, Surendranagar, IndiaAddress correspondence and reprint requests to: Mr. N. Pandya, Department of Pharmacology, C. U. Shah College of Pharmacy & Research, Wadhwan City-363030, Dist. Surendranagar, India; E-mail: [email protected], [email protected]Search for more papers by this authorDev Santani, Dev Santani Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, IndiaSearch for more papers by this authorSunita Jain, Sunita Jain Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, IndiaSearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3466.2005.tb00169.xCitations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat ABSTRACT Over the last decade important advances have been made in our understanding of the molecular events underlying cellular responses to extracellular signals. Increased understanding of signal transduction mechanisms and gene regulation involved in cardiovascular diseases has created opportunities for the discovery of novel therapeutic compounds useful for the treatment of cardiovascular disorders. One of the best-studied signalling routes is the mitogen activated protein (MAP) kinase signal transduction pathway, which plays a crucial role in many aspects of cardiovascular responses. Here, our current understanding of the MAP kinase pathway is reviewed, as well as recent advances in the design of novel agents that are able to modulate the activity of these signaling cascades. REFERENCES 1 Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–139. 10.1016/S0065-230X(08)60765-4 CASPubMedWeb of Science®Google Scholar 2 Boulton TG, Nye SH, Robbins DJ. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663–675. 10.1016/0092-8674(91)90098-J CASPubMedWeb of Science®Google Scholar 3 Boulton TG, Cobb NH. Identification of multiple extracellular signal-regulated kinases (ERKs) with anti-peptide antibodies. Cell Regul 1991; 2: 357–371. 10.1091/mbc.2.5.357 CASPubMedWeb of Science®Google Scholar 4 Cobb MH, Boulton TG, Robbins DJ. Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 1991; 2: 965–978. 10.1091/mbc.2.12.965 CASPubMedWeb of Science®Google Scholar 5 Todd JL, Tanner KG, Denu JM. Extracellular regulated kinases (ERK) 1 & ERK2 are authentic substrates for the dual specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J Biol Chem 1999; 274: 13271–13280. 10.1074/jbc.274.19.13271 CASPubMedWeb of Science®Google Scholar 6 Yang DD, Conze D, Whitmarsh AJ et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998; 9: 575–585. 10.1016/S1074-7613(00)80640-8 CASPubMedWeb of Science®Google Scholar 7 Ono K, Han J. The P38 signal transduction pathway: Activation and function. Cell Signal 2000; 12: 1–13. 10.1016/S0898-6568(99)00071-6 CASPubMedWeb of Science®Google Scholar 8 Foltz IN, Lee JC, Young PR. Hemopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen-activated protein kinase pathway. J Biol Chem 1997; 272: 3296–3301. 10.1074/jbc.272.6.3296 CASPubMedWeb of Science®Google Scholar 9 Nagata Y, Moriguchi T, Nishida E, Tokodoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 1997; 90: 929–934. 10.1182/blood.V90.3.929 CASPubMedWeb of Science®Google Scholar 10 Verma A, Deb DK, Sassano A, et al. Activation of the p38 MAP kinase pathway mediates the suppressive effects of Type I interferons and transforming growth factor beta on normal hematopoiesis. J Biol Chem 2002; 277: 7726–7735. 10.1074/jbc.M106640200 CASPubMedWeb of Science®Google Scholar 11 Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38 in erythropoietin expression: A role for stress kinases in erythropoiesis. Cell 2000; 102: 221–231. 10.1016/S0092-8674(00)00027-1 CASPubMedWeb of Science®Google Scholar 12 Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999; 31: 1429–1434. 10.1006/jmcc.1999.0979 CASPubMedWeb of Science®Google Scholar 13 Cain BS, Meldrum DR, Meng X, et al. p38-MAPK inhibition decreases TNF production and enhances post-ischemic human myocardial function. J Surg Res 1999; 83: 7–12. 10.1006/jsre.1998.5548 CASPubMedWeb of Science®Google Scholar 14 Zheng M, Zhang SJ, Zhu WZ, Ziman B, Kobilka B, Xiao RP. β2-Adrenergic receptor-induced p38-MAPK activation is mediated by protein kinase A rather than by Gi or Gβ (in adult mouse cardiomyocytes. J Biol Chem 2000; 275: 40635–40640. 10.1074/jbc.M006325200 CASPubMedWeb of Science®Google Scholar 15 Liao P, Wang SQ, Wang S, Zheng M, et al. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 2002; 90: 190–196. 10.1161/hh0202.104220 CASPubMedWeb of Science®Google Scholar 16 Grossman W. Cardiac hypertrophy: Useful adaptation or pathologic process Am J Med 1980; 69: 576–83. 10.1016/0002-9343(80)90471-4 PubMedWeb of Science®Google Scholar 17 Chien KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993; 55: 77–95. 10.1146/annurev.ph.55.030193.000453 CASPubMedWeb of Science®Google Scholar 18 Chien KR, Grace AA. in: E Braunwald, ed., Heart disease: A textbook of cardiovascular medicine. 5th Ed., Philadelphia : W. B. Saunders Co., 1996; 1626–1649. Google Scholar 19 Yibin W, Shuang H, Valerie PS, Joan HB, Jiahuai H, Kenneth RC. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998; 273: 2161–2168. 10.1074/jbc.273.4.2161 CASPubMedWeb of Science®Google Scholar 20 Post GR, Goldstein D, Thuerauf D, Glembotski CC, Brown JH. Dissociation of p44 and p42 mitogen activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 1996; 271: 8452–8457. 10.1074/jbc.271.14.8452 CASPubMedWeb of Science®Google Scholar 21 Ramirez MT, Sah VP, Zhao XL, Hunter JJ, Chien KR, Brown JH. The MEKK-JNK pathway is stimulated by α-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem 1997; 272: 14057–14061. 10.1074/jbc.272.22.14057 CASPubMedWeb of Science®Google Scholar 22 Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 1998; 8: 59–64. 10.1016/S1050-1738(97)00133-3 CASPubMedWeb of Science®Google Scholar 23 Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86: 494–501. 10.1161/01.RES.86.5.494 CASPubMedWeb of Science®Google Scholar 24 Yoshizumi M, Tsuchiya K, Tamaki T. Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease. J Med Invest 2001; 48: 11–24. CASPubMedGoogle Scholar 25 Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175–83. 10.1161/01.ATV.20.10.2175 CASPubMedWeb of Science®Google Scholar 26 Patterson C, Ruef J, Madamanchi NR, et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that P47 (Phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999; 274: 19814–19822. 10.1074/jbc.274.28.19814 CASPubMedWeb of Science®Google Scholar 27 Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. P22 phox is a critical component of the superoxide generating NADH/NADPH oxidase system and regulates angiotensin II induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317–23321. 10.1074/jbc.271.38.23317 CASPubMedWeb of Science®Google Scholar 28 Fei J, Veidt C, Soto U, Elsing C, Jahn L, Kreuzer J. Endothelin-1 and smooth muscle cells: Induction of jun amino terminal kinase through an oxygen radical-sensitive mechanism. Arterioscler Thromb Vasc Biol 2000; 20: 1244–1249. 10.1161/01.ATV.20.5.1244 CASPubMedWeb of Science®Google Scholar 29 Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and P38 kinases by reactive oxygen species. J Biol Chem 2000; 275: 11706–11712. 10.1074/jbc.275.16.11706 CASPubMedWeb of Science®Google Scholar 30 Ishida M, Ishida T, Thomas SM, Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 1998; 82: 7–12. 10.1161/01.RES.82.1.7 CASPubMedWeb of Science®Google Scholar 31 Yoshizumi M, Kim S, Kagami S, Hamaguchi A. Effect of endothelin-1 on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 1998; 125: 1019–27. 10.1038/sj.bjp.0702141 CASPubMedWeb of Science®Google Scholar 32 Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Tamaki T. Antioxidants inhibit JNK and P38 MAPK activation but not ERK1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res 2001; 24: 251–261. 10.1291/hypres.24.251 CASPubMedWeb of Science®Google Scholar 33 Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Suzaki Y, Abe S. Antioxidants inhibit endothelin-1 induced proliferation of vascular smooth muscle cells via the inhibition of mitogen-activated protein (MAP) kinase and activator protein-1 (AP-1). Biochem Pharmacol 2002; 64: 1521–1531. 10.1016/S0006-2952(02)01349-7 CASPubMedWeb of Science®Google Scholar 34 Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D. Role of caspases in ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004; 94: 370–376. 10.1161/01.RES.0000113782.07824.BE CASPubMedWeb of Science®Google Scholar 35 Bors W, Heller W, Michael C, Saran M. Flavonoids as antioxidants: Determination of radical-scavenging efficiencies. Methods Enzymol 1990; 186: 343–355. 10.1016/0076-6879(90)86128-I CASPubMedWeb of Science®Google Scholar 36 Yoshizumi M, Tsuchiya K, Kirima K, Kyaw M, Suzaki Y, Tamaki T. Quercetin inhibits Shc- and phosphatidylinositol 3-kinase-mediated c-jun-N-terminal kinase activation by angiotensin II in cultured rat aortic smooth muscle cells. Mol Pharmacol 2001; 60: 656–65. CASPubMedWeb of Science®Google Scholar 37 Moon SK, Cho GO, Jung SJ, Gal SW, Kwon TK, Lee YC. Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: Role of ERK1/2, cell cycle regulation, and matrix metalloproteinase-9. Biochem Biophys Res Commun 2003; 301: 1069–1078. 10.1016/S0006-291X(03)00091-3 CASPubMedWeb of Science®Google Scholar Citing Literature Volume23, Issue3September 2005Pages 247-254 ReferencesRelatedInformation

Referência(s)